Mostrar o rexistro simple do ítem
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies
dc.contributor.author | Castellano, Daniel | |
dc.contributor.author | Maroto, José Pablo | |
dc.contributor.author | Espinosa, Enrique | |
dc.contributor.author | Grande, Enrique | |
dc.contributor.author | Bolós Fernández, Victoria | |
dc.contributor.author | Llinares, Julia | |
dc.contributor.author | Esteban, Emilio | |
dc.contributor.author | González del Alba, Aránzazu | |
dc.contributor.author | Climent, Miguel Ángel | |
dc.contributor.author | Arranz, José Ángel | |
dc.contributor.author | Méndez, María José | |
dc.contributor.author | Fernández Parra, Eva | |
dc.contributor.author | Antón-Aparicio, Luis M. | |
dc.contributor.author | Bayona, Cristina | |
dc.contributor.author | Gallegos, Isabel | |
dc.contributor.author | Gallardo, Enrique | |
dc.contributor.author | Samaniego, Luz | |
dc.contributor.author | García Donas, Jesús | |
dc.date.accessioned | 2021-06-21T08:56:29Z | |
dc.date.available | 2021-06-21T08:56:29Z | |
dc.date.issued | 2017-08-28 | |
dc.identifier.citation | Castellano D, Maroto JP, Espinosa E, Grande E, Bolós MV, Llinares J, et al. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies. Expert Opin Drug Saf. 2018:17(6):573-579 | es_ES |
dc.identifier.issn | 1474-0338 | |
dc.identifier.uri | http://hdl.handle.net/2183/28112 | |
dc.description.abstract | [Abstract] Background: A pivotal, randomized, phase III trial demonstrated a statistically significant superiority of sunitinib over interferon-α in metastatic renal cell carcinoma (mRCC) patients. Objective: To evaluate the effectiveness and safety of sunitinib in patients with advanced or mRCC in routine clinical practice. Methods: Retrospective pooled analysis of clinical data from three observational and prospective studies carried out between 2007 and 2011 in 33 Spanish hospitals. Tumor response, Progression-free survival (PFS) and overall survival (OS), and main sunitinib-related toxicities were registered. Results: 224 patients were analyzed. Median PFS 10.6 months (95% CI: 9.02–12.25), median OS 21.9 months (95% CI: 17.2–26.6). Objective response rate (ORR) 43.8% (95% CI: 36.8–50.7). Median time to PR was 3.8 months (95% CI: 3.86–5.99) and to CR 8.2 months (95% CI: 4.75–9.77). The most common ≥ grade-3 AEs were asthenia/fatigue (18.7%), hand-foot syndrome (6.2%), hypertension (5.8%) and neutropenia (4.8%). Hand-foot syndrome, diarrhea and mucositis were confirmed as independent predictors for PFS and/or OS in a multivariate analysis (p < 0.05) Conclusions: Outcomes with sunitinib in daily clinical practice resemble those obtained in clinical trials. Long-term benefit with sunitinib is possible in advanced RCC patients but the appropriate management of toxicities is mandatory to enable patients to remain on treatment. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Taylor & Francis | es_ES |
dc.relation.uri | https://doi.org/10.1080/14740338.2017.1330410 | es_ES |
dc.rights | This is an accepted manuscript of an article published by Taylor & Francis in "Expert Opinion on Drug Safety", avaliable online at Taylor & Francis Online web. | es_ES |
dc.subject | Effectiveness | es_ES |
dc.subject | Routine clinical practice | es_ES |
dc.subject | Safety | es_ES |
dc.subject | Sunitib | es_ES |
dc.title | Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.access | info:eu-repo/semantics/openAccess | es_ES |
UDC.journalTitle | Expert Opinion on Drug Safety | es_ES |
UDC.volume | 17 | es_ES |
UDC.issue | 6 | es_ES |
UDC.startPage | 573 | es_ES |
UDC.endPage | 579 | es_ES |
Ficheiros no ítem
Este ítem aparece na(s) seguinte(s) colección(s)
-
INIBIC-OCT - Artigos [21]